ABBV — Recent News Coverage

All news mentioning ABBV in ESEN's AI-graded feed

News stories with ABBV as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ABBV. See /coverage/ABBV for the 30-day aggregate.

7 articles Updated: 2026-06-19 12:58 UTC Filter: Ticker: $ABBV
FINANCE.YAHOO.COM · 2026-06-17 NEUTRAL BULLISH CORR0.42

AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

$ABBV
◈ ESEN AI
AbbVie's Phase 3 CLL14 trial data release on fixed-duration venetoclax-based combination therapy represents a clinical validation milestone for the company's oncology portfolio. The presentation at the European Hematolo…
SEEKINGALPHA.COM · 2026-06-16 NEUTRAL BULLISH CORR0.58

AbbVie: Maintaining My Strong Buy Rating After Label Expansion (NYSE:ABBV)

$ABBV
◈ ESEN AI
AbbVie (ABBV) demonstrates portfolio momentum through label expansion driving near-term upside, contingent on successful commercialization of newer assets. The analyst maintains conviction on the stock despite structura…
FINANCE.YAHOO.COM · 2026-06-16 NEUTRAL BULLISH CORR0.58

AbbVie Stock Will Hit $300 on This Date

$ABBV
◈ ESEN AI
AbbVie (ABBV) has demonstrated solid Q1 2026 operational momentum, with immunology division revenue reaching $7.29 billion and flagship products Skyrizi and Rinvoq posting double-digit growth rates (30.9% and 23.3% resp…
FINANCE.YAHOO.COM · 2026-06-16 LOW NEUTRAL CORR0.42

FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

$FHLC $IYH $JNJ $ABBV
◈ ESEN AI
This comparative analysis examines two healthcare-focused ETFs—FHLC and IYH—highlighting how structural differences in portfolio construction and asset base influence their respective risk-return profiles. The distincti…
SEEKINGALPHA.COM · 2026-06-12 NEUTRAL NEUTRAL CORR0.42

AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy (NYSE:ABBV)

$ABBV
◈ ESEN AI
AbbVie (ABBV) faces a critical inflection point as it transitions away from Humira, historically its blockbuster franchise. The successful replacement with Skyrizi and Rinvoq demonstrates operational execution, but the …
SEEKINGALPHA.COM · 2026-06-11 NEUTRAL BULLISH CORR0.52

AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV)

$ABBV
◈ ESEN AI
AbbVie (ABBV) presents a valuation arbitrage opportunity where a company exhibiting growth-stage pharmaceutical fundamentals trades at discounts typically reserved for mature, slower-growing players. The thesis hinges o…
ETFTRENDS.COM · 2026-06-11 LOW NEUTRAL CORR0.32

Inside ASD: The Story Behind the First Autism ETF

$LFST $ABBV $JNJ
◈ ESEN AI
Defiance has launched a specialized autism-focused ETF that integrates autism research and advocacy into its investment thesis, representing a niche thematic strategy within the broader health care sector. The product i…
EXPLORE OTHER FILTERS